Nivolumab-Induced Autoimmune-Like Cholestatic Hepatitis in a Liver Transplant Recipient

Research output: Contribution to journalArticlepeer-review


Cancer treatment has taken giant strides in recent years with the advent of immunotherapy, including checkpoint inhibitors. The use of these medications in liver transplant recipients has been debated, and the added effect of previous hepatitis C infection on the immune system in this setting, is poorly understood. We present a case of cholestatic hepatitis after the treatment of recurrent hepatocellular carcinoma with nivolumab in the post-transplant period. Understanding the pathophysiology is relevant to improving the management of this type of liver injury and expanding our knowledge of programmed death-1 inhibitors in liver transplant recipients.

Original languageEnglish (US)
Pages (from-to)e00416
JournalACG Case Reports Journal
Issue number7
StatePublished - Jul 2020

Bibliographical note

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.

PubMed: MeSH publication types

  • Case Reports


Dive into the research topics of 'Nivolumab-Induced Autoimmune-Like Cholestatic Hepatitis in a Liver Transplant Recipient'. Together they form a unique fingerprint.

Cite this